(-0.08%) 5 183.78 points
(0.20%) 38 962 points
(-0.26%) 16 291 points
(0.85%) $79.05
(0.50%) $2.22
(0.13%) $2 327.20
(0.48%) $27.68
(-0.28%) $985.65
(0.05%) $0.930
(-0.04%) $10.89
(0.08%) $0.800
(0.34%) $91.75
5 days till quarter result
(bmo 2024-05-13)
Expected move: +/- 21.05%
-0.13% $ 7.53
@ $8.91
Emitido: 14 feb 2024 @ 14:26
Retorno: -15.49%
Señal anterior: feb 13 - 15:22
Señal anterior:
Retorno: -1.22 %
Live Chart Being Loaded With Signals
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States...
Stats | |
---|---|
Volumen de hoy | 60 217.00 |
Volumen promedio | 618 170 |
Capitalización de mercado | 468.02M |
EPS | $0 ( 2024-02-27 ) |
Próxima fecha de ganancias | ( $-0.440 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -4.74 |
ATR14 | $0.0160 (0.21%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-18 | Horn Patrick Taylor | Buy | 400 000 | Stock Option (right to buy) |
2024-03-18 | Horn Patrick Taylor | Sell | 0 | No securities are beneficially owned |
2024-03-08 | Tourangeau Greg | Sell | 4 884 | Common Stock |
2024-03-04 | Sapir Alex | Buy | 43 360 | Common Stock |
2024-01-26 | Tourangeau Greg | Buy | 83 820 | Stock Option (right to buy) |
INSIDER POWER |
---|
20.70 |
Last 98 transactions |
Buy: 8 691 029 | Sell: 9 119 346 |
Volumen Correlación
Fulcrum Therapeutics Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
ABST | 0.942 |
CSX | 0.939 |
MULN | 0.929 |
VNET | 0.928 |
ALLO | 0.927 |
RLMD | 0.92 |
CNDT | 0.919 |
IDLB | 0.918 |
PTH | 0.917 |
EGAN | 0.917 |
10 Correlaciones Más Negativas | |
---|---|
RMRM | -0.949 |
RDUS | -0.927 |
XOG | -0.9 |
TYHT | -0.895 |
EPZM | -0.881 |
RTPY | -0.876 |
SVOK | -0.874 |
OPCH | -0.871 |
SYKE | -0.868 |
HSTM | -0.864 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Fulcrum Therapeutics Inc Correlación - Moneda/Commodity
Fulcrum Therapeutics Inc Finanzas
Annual | 2023 |
Ingresos: | $2.81M |
Beneficio Bruto: | $633 000 (22.57 %) |
EPS: | $-1.590 |
FY | 2023 |
Ingresos: | $2.81M |
Beneficio Bruto: | $633 000 (22.57 %) |
EPS: | $-1.590 |
FY | 2022 |
Ingresos: | $6.34M |
Beneficio Bruto: | $3.93M (61.94 %) |
EPS: | $-2.35 |
FY | 2021 |
Ingresos: | $19.16M |
Beneficio Bruto: | $19.16M (100.00 %) |
EPS: | $-2.29 |
Financial Reports:
No articles found.
Fulcrum Therapeutics Inc
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico